We did a lot of work to implement our project into the real world commercially. We create a patent to protect our ideas and technology from being stolen by other companies. We can sell our technology and ideas to medical companies. They can then legally use this technology and thought to create medicines or proteins to protect and even cure patients. Our project is something that medicine companies could not get from other companies. That is why we could successfully sell our technology to companies without a lot of obstacles.
Angiogenin has been recognized to play important roles in various physiological and pathological processes, especially in neurodegenerative diseases.
In our project, we created a recombinant E. coli by introducing the plamid pET-28a-rANG that can secret functional ANG protein, which could possibly serve as an in vitro method to massive produce ANG for clinical use. As seen in figure above, we have already obtained the Freeze-dried powder of the ANG protein produced by our engineered E. coli.
In addition, we conducted the RNA degradation test which turn out that the protein possesses ribonuclease activity as we expected.
In future applications, the product we get may have two directions of develop, but all in the clinical medicine aspect. One is to directly invent a new drug with the protein product of this gene and the other one is to explore its pharmacology regarding the relevant diseases which could be used to develop more new drugs.
The first kind of drug may have an effect on adjusting the nerve system, treating diseases like inflammation and the further developed drugs may be a possible treatment of some present incurable diseases such as PD and tumor. However, the overuse of ANG will also overpromote the generation of endothelial cells and vessels and may even cause cancer in some situations, so the correct usage of this drug shall be also necessary for being studied.
According to relevant data, among the 65-year-olds, one in ten people are Parkinson's disease patients; among the 85-year-olds, the number of people who have Parkinson's disease reaches 30%-50%. The research progress and molecular biological characteristics of Angiopoietin and its related proteins are reviewed. So far, four kinds of Angiopoietin and some isoforms or variants of Angiopoietin have been discovered. These proteins have a common structure: a signal peptide related to secretion at the amino terminus, a helix-like domain that mediates homo-oligomers, and a fibrinogen-like domain that mediates ligand activity at the carboxyl terminus.
The theory we have resulted in a unique product (but not medicine), which will be studied and researched by staff members in the collaborated pharmaceutical company), and the final medical products will be entirely produced and owned by the partner company. The outcome of our company remains with unknown effects on medicine. However, the result will be owned by our target group (pharmaceutical company).
We will market our product using many different ways. For example, online surveys, email marketing, mobile marketing, and social media marketing are considered the cheapest among all types of marketing. Since we are a brand new company, we do not have many budgets available for us, so we would consider the ways I listed above first. Once we have more budget allowed, we might try other ways of marketing our product. For example, printed marketing materials, such as brochures, flyers, business cards, etc. We can also try trade shows and other marketing that cost some money.
During the experimental work, the main challenges were the plasmid DNA extraction and the protein purification process. One aspect of the difficulty is the continuous low concentration of plasmid DNA when we first extracted them. But as we navigate through and become more familiar with the long process, we successfully extracted with an ideal concentration.
Moreover, heterologous overexpression often results in low expression levels and inactive protein due to insufficient membrane insertion and folding or lack of post-translational modifications. And over-expression of membrane proteins can be toxic to the cell. Nevertheless, eventually, we obtained the freeze-dried protein powder. But with no doubt, we will further solidify this part of the work.
Before our product come into a real application, there are still some concerns regarding our Angiogenin protein. We need to conduct more experiments and tests to further ensure its purity, stability and biological activity. In addition, we would further focus on the yield issues, storage conditions and how to use our products to determine the dose of curing some present incurable diseases.